September 18, 2025Ophthalmologica

Brolucizumab for Wet Age-related Macular Degeneration in Switch Patients: Long-Term Real-World Experience from a Tertiary Center

View Full Paper

Ask AI

Bookmark

Mean BCVA improved significantly from 41.1 to 50.7 ETDRS letters after three years of brolucizumab treatment.
Patients experienced a significant reduction in CST from 371.3 to 299.1 microns, highlighting anatomical improvement.
Treatment intervals decreased over the three years, indicating a reduced burden with an average of 3.6 injections in the third year.
Adverse events were minimal, occurring in only four patients, confirming brolucizumab's favorable safety profile.

Discussion

No takes yet. Share an insight, caveat, or question.

Observational cohort study shows significant improvement in vision and reduced treatment burden in nAMD patients, suggesting brolucizumab's efficacy.

Scupola et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational cohort study shows significant improvement in vision and reduced treatment burden in nAMD patients, suggesting brolucizumab's efficacy.